MA27606A1 - Association destinée au traitement de l'ADHD - Google Patents

Association destinée au traitement de l'ADHD

Info

Publication number
MA27606A1
MA27606A1 MA28325A MA28325A MA27606A1 MA 27606 A1 MA27606 A1 MA 27606A1 MA 28325 A MA28325 A MA 28325A MA 28325 A MA28325 A MA 28325A MA 27606 A1 MA27606 A1 MA 27606A1
Authority
MA
Morocco
Prior art keywords
adhd
association
treatment
psychostimulants
nachr
Prior art date
Application number
MA28325A
Other languages
English (en)
Inventor
Vincent Edward Groppi Jr
Eric Jon Jacobsen
Jason Kenneth Myers
David Walter Piotrowski
Bruce Nelsen Rogers
Daniel Patrick Walker
Donn Gregory Wishka
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MA27606A1 publication Critical patent/MA27606A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Association destinée au traitement de l'ADHD La présente invention concerne des compositions et des méthodes de traitement de l'ADHD avec un agoniste total des récepteurs nicotiniques (alpha)7 d'acetylcholine (nAChR) et des psychostimulants et/ou des inhibiteurs de réabsorption de monoamines.
MA28325A 2002-12-11 2005-06-10 Association destinée au traitement de l'ADHD MA27606A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43258602P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
MA27606A1 true MA27606A1 (fr) 2005-11-01

Family

ID=32507968

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28325A MA27606A1 (fr) 2002-12-11 2005-06-10 Association destinée au traitement de l'ADHD

Country Status (23)

Country Link
US (1) US20050107425A1 (fr)
EP (1) EP1572300A1 (fr)
JP (1) JP2006510663A (fr)
KR (1) KR20050085538A (fr)
CN (1) CN1735441A (fr)
AP (1) AP2005003336A0 (fr)
AU (1) AU2003283656A1 (fr)
BR (1) BR0317229A (fr)
CA (1) CA2509142A1 (fr)
CO (1) CO5700801A2 (fr)
CR (1) CR7868A (fr)
EA (1) EA200500783A1 (fr)
EC (1) ECSP055852A (fr)
HR (1) HRP20050522A2 (fr)
IS (1) IS7858A (fr)
MA (1) MA27606A1 (fr)
MX (1) MXPA05006336A (fr)
NO (1) NO20053185L (fr)
OA (1) OA12969A (fr)
PL (1) PL377552A1 (fr)
TN (1) TNSN05158A1 (fr)
WO (1) WO2004052461A1 (fr)
ZA (1) ZA200504338B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0310867D0 (en) * 2003-05-12 2003-06-18 Novartis Ag Organic compounds
CN103724343A (zh) 2004-03-25 2014-04-16 记忆药物公司 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2008083442A1 (fr) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Procédé pour la formulation de médicaments mixtes contre tdah
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
BRPI0908098A2 (pt) * 2008-02-19 2015-08-18 Adolor Corp Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2
WO2010059618A1 (fr) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantylbenzamides
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
DK2571874T3 (en) 2010-05-17 2016-05-17 Forum Pharmaceuticals Inc A crystalline form of (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide hydrochloride monohydrate
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
CA2872005A1 (fr) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Procedes de maintien, de traitement ou d'amelioration de la fonction cognitive
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
KR102629135B1 (ko) 2021-08-19 2024-01-29 단국대학교 천안캠퍼스 산학협력단 Kds2010을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
KR102597711B1 (ko) 2021-08-20 2023-11-06 단국대학교 천안캠퍼스 산학협력단 Snap5114을 유효성분으로 포함하는 주의력결핍 과잉행동장애의 예방 또는 치료용 약학적 조성물
WO2023022269A1 (fr) 2021-08-20 2023-02-23 단국대학교 천안캠퍼스 산학협력단 Composition pharmaceutique pour prévenir ou traiter un trouble déficitaire de l'attention avec hyperactivité
KR20230027862A (ko) 2021-08-20 2023-02-28 단국대학교 천안캠퍼스 산학협력단 주의력결핍 과잉행동장애의 진단을 위한 gat-3의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
EP1572300A1 (fr) 2005-09-14
CN1735441A (zh) 2006-02-15
AU2003283656A1 (en) 2004-06-30
NO20053185L (no) 2005-08-17
AP2005003336A0 (en) 2005-06-30
KR20050085538A (ko) 2005-08-29
CR7868A (es) 2005-07-08
BR0317229A (pt) 2005-11-01
CO5700801A2 (es) 2006-11-30
ECSP055852A (es) 2005-09-20
US20050107425A1 (en) 2005-05-19
NO20053185D0 (no) 2005-06-29
MXPA05006336A (es) 2005-08-26
PL377552A1 (pl) 2006-02-06
EA200500783A1 (ru) 2005-12-29
JP2006510663A (ja) 2006-03-30
WO2004052461A1 (fr) 2004-06-24
TNSN05158A1 (fr) 2007-05-14
HRP20050522A2 (en) 2005-12-31
OA12969A (en) 2006-10-13
ZA200504338B (en) 2006-07-26
CA2509142A1 (fr) 2004-06-24
IS7858A (is) 2005-05-23

Similar Documents

Publication Publication Date Title
MA27606A1 (fr) Association destinée au traitement de l'ADHD
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
HK1074573A1 (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2004052348A3 (fr) Traitement de maladies a l'aide de combinaisons d'agonistes du recepteur nicotinique de l'acetylcholine alpha 7 et d'autres composes
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
AP2003002824A0 (en) Gyrase inhibitors and uses thereof
SG155054A1 (en) Human anti- neutralizing antibodies as selective pathway inhibitors
AU4455896A (en) A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses
ATE236629T1 (de) Verwendung heterocyclischer verbindungen als dopamin-d 3 liganden
ATE214276T1 (de) Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE342253T1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
ATE520709T1 (de) Campylobacter-polypeptide und verwendungsverfahren
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
ATE345793T1 (de) Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
ATE348812T1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
EP1254260A4 (fr) Methodes pour diagnostiquer et traiter une maladie du coeur
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
MXPA03004547A (es) Agonistas receptores de d4 de dopamina selectivos para el tratamiento de disfuncion sexual.
WO2004009029A3 (fr) Compositions et procedes de traitement et de prevention d'infections
IL140858A0 (en) Endogenous constitutively activated g protein-coupled orphan receptors
MA31562B1 (fr) Macrocycles et leurs utilisations